Yorktown Management & Research Company’s Corcept Therapeutics CORT Stock Holding History

Yorktown Management & Research Company’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$565K	Buy	+6,500	New	+$392K	0.35%	106

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Yorktown Management & Research Company's CORT Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 6,500 shares worth $565K. The stake represents 0.35% of the portfolio and ranks #106 among its holdings.

205 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Yorktown Management & Research Company held 6,500 shares of Corcept Therapeutics worth $565K as of Q2 2026.
Corcept Therapeutics was a new Yorktown Management & Research Company position in Q2 2026.
Corcept Therapeutics made up 0.35% of Yorktown Management & Research Company's portfolio in Q2 2026, its #106 holding.
205 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.